A high proportion of pediatric, randomized controlled trials (RCTs) have a high risk for bias, particularly those that are industry-funded or involve assessment of behavioral/educational interventions, but trial registration is linked to less risk of bias, according to research published online July 12 in Pediatrics, HealthDay News reported.
A high proportion of pediatric, randomized controlled trials (RCTs) have a high risk for bias, particularly those that are industry-funded or involve assessment of behavioral/educational interventions, but trial registration is linked to less risk of bias, according to research published online July 12 in Pediatrics, HealthDay News reported.
Michael T. Crocetti, MD, MPH, of the Johns Hopkins Bayview Medical Center in Baltimore, Md., and colleagues evaluated pediatric RCTs from 8 high-impact journals for risk of bias within 6 domains: randomized sequence generation; allocation concealment; masking of participants, personnel, and outcome assessors; incomplete outcome data reporting; selective outcome reporting; and other sources of bias. Methods developed by the Cochran Collaboration were used to evaluate each RCT.
The researchers found that many RCTs had a high risk of bias in the domains of sequence generation and allocation concealment. Higher risk of bias for sequence generation was seen in industry-funded trials compared to government-funded trials (adjusted odds ratio [aOR], 6.1), and in RCTs involving assessment of behavioral/educational interventions compared to drug trials (aOR, 2.8). Behavioral/education trials were also more likely to have a high risk of bias for the domain of allocation concealment (aOR, 4.09). Registered trials were found to have a lower risk of sequence generation bias than non-registered trials (aOR, 0.33). RCTs with higher numbers of authors were less likely to have a high risk of bias for incomplete outcome reporting (aOR, 0.78).
“Registered trials were 68% less likely to have a high risk of bias for sequence generation, compared with non-registered trials. Increasing the number of pediatric RCTs that are registered would make trial information more accessible to the public and also could be a marker for a reduced risk of bias in trial design,&rquot; the authors wrote.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More